IUD insertion in early postpartum period linked to perforation risk: Lancet

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-06-09 03:45 GMT   |   Update On 2022-06-09 10:16 GMT

USA: A new study conducted by Susan D. Reed and colleagues showed that the risk of uterine perforation is roughly seven times higher with intrauterine devices (IUD) placement at 4 days to 6 weeks or less postpartum. Perforation remains an extremely unusual occurrence in all clinical time periods. The findings of this study were published in The Lancet.

There have been few reports of perforation risk associated with IUDs put shortly postpartum and among non-postpartum patients, and prior studies with limited 12-month follow-ups underestimated the risk. Breastfeeding during IUD implantation, as well as an insertion within 36 weeks postpartum, has been linked to a higher risk of uterine perforation.

As a result, this study was conducted to analyze and evaluate the incidence and hazards of IUD-related uterine perforations at non-postpartum and post-partum intervals at IUD implantation, as well as to investigate the influence of breastfeeding on these outcomes among post-partum people.

This was a multisite cohort study in the United States that used electronic health records (EHR). Three healthcare systems and one site that utilized data from a health-care information exchange were used as study sites. Individuals aged 50 and under who had an IUD inserted between January 1, 2001, and April 30, 2018, were included in the research. Individuals were not eligible if they had not been enrolled in the healthcare system for at least 12 months prior to IUD placement.

Advertisement

This study's primary outcome was any IUD-related uterine perforation diagnosis for the first IUD implantation throughout this time period. There were both total and partial IUD-related perforations found. Chart abstraction was performed in order to evaluate EHR-based algorithms or check holes. The raw rate and accumulated incidence of uterine perforation were calculated using non-postpartum and post-partum periods at IUD placement in the whole cohort, as well as breastfeeding status in a post-partum subcohort. The Cox models calculated the crude and adjusted hazard ratios (aHRs).

The key findings of this study were as follows:

1. The researchers examined data from 326 658 people in the entire cohort and 94 817 people in the post-partum subcohort.

2. 1008 uterine perforations (51.2% complete) were found in the entire cohort, with the non-postpartum group having the lowest 5-year cumulative incidence.

3. The aHR for the post-partum interval compared to the non-postpartum interval varied from 2.73 to 6.71.

4. The post-partum subcohort of persons with breastfeeding data had 673 uterine perforations (62% complete), a 5-year cumulative incidence of 1.37%, and an elevated risk with nursing.

In conclusion, despite a modestly increased risk of perforation during IUD installation with nursing, the advantages of breastfeeding and effective contraception often exceed the risks and should have no clinical impact. To ensure an IUD implantation, the IUD insertion date should be based on an individual's desire for an IUD contraceptive and patient convenience. Individuals at increased risk of uterine perforation should be closely monitored.

Reference:

Reed, S. D., Zhou, X., Ichikawa, L., Gatz, J. L., Peipert, J. F., Armstrong, M. A., Raine-Bennett, T., Getahun, D., Fassett, M. J., Postlethwaite, D. A., Shi, J. M., … Anthony, M. S. (2022). Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study. In The Lancet (Vol. 399, Issue 10341, pp. 2103–2112). Elsevier BV. https://doi.org/10.1016/s0140-6736(22)00015-0

Tags:    
Article Source : The Lancet

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News